BOUCHERVILLE, QUEBEC--(Marketwire - March 24, 2010) - Biotonix (2010) Inc. (TSX VENTURE: BTX) (“Biotonix”), a leader in postural health and fitness, announced that its shares will begin trading today on the Toronto Venture Stock Exchange (TSX-V) under the symbol BTX at market opening. This follows the closing of a qualifying transaction and concomitant $2.5 million financing on March 18. The Company also launched today a completely redesigned website in order to better reflect its leadership position in delivering innovative web-based health solutions for posture correction and fitness.
“This is a major step which will give Biotonix the resources to further expand its array of web-based software solutions for posture correction and fitness, and ensure long-term growth with the development of orthotics for the foot and back,” said Dr Sylvain Guimond, D.O., Ph.D., President of Biotonix.
User-friendly and easier to navigate, the new website features a testimonial by hockey legend Mario Lemieux on how the Biotonix 10-week program helped free him from chronic back pain, as well as new sections about the solutions and technologies, and exclusive presentations on posture and health by Dr Sylvain Guimond, D.O., Ph.D., President of Biotonix. The site also includes a new client support center, investor center and an entire segment dedicated to science. Testimonials from healthcare professionals, healthcare and fitness organizations about their experience with the Biotonix applications for posture correction and fitness can be found in the Customers’ section.
“I wanted to share my story because I had tried many different approaches and treatments for my back, but none had yield appreciable results. Biotonix’s non-invasive method and system not only freed me from back pain, it also helped me regain my physical strength,” commented Mario Lemieux, one of the principal owners and Chairman of the Pittsburgh Penguins. Mr. Lemieux concluded, “I believe Biotonix’s comprehensive approach to posture correction and fitness sets new standards in the health and wellness marketplace.”
ABOUT THE BIOTONIX SYSTEM
Biotonix’s core technology is a web-based, imaging software system which is easy to use, non-invasive and provides a complete individualized assessment of musculoskeletal form and function, postural deviation detection, and corresponding corrective exercises. All aspects of the Biotonix system are based on well-established scientific principles, and the exercises are guided by world recognized guidelines, recommended by authorities, and research at the UQTR and McGill University which has shown the system to be both valid and reliable. The Biotonix system is listed as a Class 1 Medical Device both by the United States of America’s Food and Drug Administration (FDA) and Health Canada.
BIOTONIX PROFILE
Biotonix (TSX VENTURE: BTX) offers innovative health solutions for posture correction using a web-based imaging software technology. Biotonix is currently developing novel orthotics for the back and foot, also geared specifically toward improving posture. For more information please visit www.biotonix.com
BIOTONIX’S FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, no history of profitability, future financing, intellectual property and patents, key personnel, competitive marketplace, technology obsolescence, share price volatility and other risks detailed from time to time in the Company’s filings. While Biotonix anticipates that subsequent events and developments may cause its views to change, Biotonix specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Biotonix
Louise St-Onge
CEO
514-892-3028
Biotonix
Julie M. Thibodeau, B.Sc., MBA
VP, Corporate communications and investor relations
514-840-0004 ext 223
thibodeauj@biotonix.com
www.biotonix.com